Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00176813
Status:
COMPLETED
Last Update Posted:
2008-05-06
First Post:
2005-09-09
Brief Title:
Gemcitabine Cisplatin and Celecoxib Treatment of Metastatic Pancreatic Cancer
Sponsor:
University of Michigan Rogel Cancer Center
Organization:
University of Michigan Rogel Cancer Center
Study Overview
Official Title:
Phase II Study of Gemcitabine Cisplatin and Celecoxib in the Treatment of Metastatic Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine an investigational experimental treatment using gemcitabine cisplatin and celecoxib Preliminary studies have shown that this experimental treatment may be effective in reducing the size of cancerous tumors andor preventing further tumor growth
This is a phase II clinical trial studying the reactions of the patients body and their tumor to the combination of gemcitabine cisplatin and celecoxib The purpose of this study is to see if the tumor responds to this treatment and to determine how long the response lasts This study will also look at what kind of side effects this experimental treatment causes and see how often these side effects occur Blood levels of celecoxib will be measured to find out how this treatment affects factors proteins involved in new blood vessel formation and tumor growth angiogenesis
This is a phase II clinical trial studying the reactions of the patients body and their tumor to the combination of gemcitabine cisplatin and celecoxib The purpose of this study is to see if the tumor responds to this treatment and to determine how long the response lasts This study will also look at what kind of side effects this experimental treatment causes and see how often these side effects occur Blood levels of celecoxib will be measured to find out how this treatment affects factors proteins involved in new blood vessel formation and tumor growth angiogenesis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| C2442 | None | None | None |